2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Salah-Eddin Al-Batran, MD, presenting abstract LBA 4001, FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma during the Gastrointestinal (Colorectal) Cancer Oral Abstract Session

Salah-Eddin Al-Batran, MD, presenting abstract LBA 4001, FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma during the Gastrointestinal (Colorectal) Cancer Oral Abstract Session

Chicago, IL - 2016 ASCO Annual Meeting - Salah-Eddin Al-Batran, MD, presenting abstract LBA 4001, FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma during the Gastrointestinal (Colorectal) Cancer Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Monday, June 6, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Phil McCarten 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org